The market for cholesterol lowering drugs is expected to grow at a CAGR of around 7.1% from 2020 to 2027 and expected to reach the market value of around US$ 27.5 Bn by 2027.

Cholesterol-Lowering Drugs, Hypolipidemic agents, or antihyperlipidemic agents are used for the treatment of high levels of fats (lipids), such as cholesterol, in the blood (hyperlipidemia). These are also known as lipid-lowering drugs. The high level of cholesterol leads to heart attacks, stroke, and may cause death from heart disease. According to a study held at Harvard, taking a statin cuts overall cardiovascular risk by 20% to nearly 50%.  According to the Centers for Disease Control and Prevention (CDC) database of 2017, more than 365,914 people have died in the United States due to coronary artery disease, and about 18.2 million adults aged 20 years and older have coronary artery disease.

Market Dynamics

The growing awareness about bad cholesterol and investigational studies held by companies to understand which drugs are well-tolerated in patients to make improvements according to the results are the primary factors driving the market growth. The increasing research activities to include bempedoic acid for the development of new drugs, healthcare providers are recommending the intake of bempedoic acid with statins to lower complications of LDL (Low-density Lipoproteins) associated with hypercholesterolemia are bolstering the market growth. The companies are harnessing the advantages of bempedoic acid to treat a host of health conditions like hypercholesterolemia as well as to treat patients with high cardiovascular disease (CVD) risks are accelerating the market growth.

On the other side, severe side effects of statins causing rhabdomyolysis and availability of generic drugs of major leading brands are anticipated to hinder the growth during the forecast period.

Segment Instance

Some of the leading drugs under the statins and fixed-dose combination segment include crestor, lipitor, livalo, lescol/lescol XL, zocor, vytorin, caduet, and others. The cholesterol absorption inhibitors, ion exchange resins, and fibrates segment include zetia, welchol, tricor, and others. The PCSK9 Inhibitor segment includes praluent, repatha, RN316, and others. Additionally, the novel cholesterol-lowering drugs segment includes juxtapid, kynamro, MK-0859, and others.

Retail Pharmacies accounted for the major revenue share in the Cholesterol Lowering Drugs Market

Based on the distribution channel, retail pharmacies are the leading segment in terms of revenue and volume both as the people used to buy due to convenience. Additionally, people are more likely to buy the prescribed medication from a reliable and better access store. Moreover, online pharmacies are likely to experience the fastest growth throughout the forecast timeframe from 2020 to 2027.  The increasing number of online stores coupled with the increasing number of online buyers, especially in developing economies is projected to create potential demand over the forecast period from the online pharmacies. The increasing number of startups, which are offerings discounts and delivering medicines to the consumers at the time, as well as offering cash on delivery feature which is creating reliability on online pharmacies, are some of the factors driving the segmental market growth.

Key Market Players

The players profiled in the report include AbbVie, Inc. (US), Amgen (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer, Inc. (US), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), and others.

Market Segmentation

Market By Drug Class

Cholesterol Absorption Inhibitors

Fibrates

Fixed-Dose Combinations

Ion Exchange Resins

Novel Cholesterol-Lowering Drugs

PCSK9 Inhibitors

Statins

Market By Disease Type

Hypercholesterolemia

Cardiovascular Diseases

Hyperlipidemia

Market By Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Market By Geography

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

TABLE OF CONTENT